Real-world Evidence of the Use of a Carfilzomib Triplet Including an Anti-CD38 Antibody in Patients With Multiple Myeloma who Have Received at Least one Prior Therapy (20200445) First published 09/11/2022 Last updated 11/03/2025 EU PAS number:EUPAS49271 Study Cancelled